Table 2. Response to M R treatment (all... | American Society of Hematology

Table 2.

Response to M+R treatment (all patients and patient subsets)

n (%)	All patients (N = 99)	Refractory to last regimen (n = 78)	Prior LOT			Age, y		Immunophenotype
n (%)	All patients (N = 99)	Refractory to last regimen (n = 78)	1 (n = 5)	2 (n = 37)	>2 (n = 57)	<75 (n = 64)	≥75 (n = 35)	Germinal center (n = 56)	Nongerminal center (n = 22)
ORR∗	24 (24.2)	15 (19.2)	1 (20.0)	9 (24.3)	14 (24.6)	16 (25.0)	8 (22.9)	11 (19.6)	5 (22.7)
CR	12 (12.1)	6 (7.7)	0	4 (10.8)	8 (14.0)	9 (14.1)	3 (8.6)	4 (7.1)	3 (13.6)
PR	12 (12.1)	9 (11.5)	1 (20.0)	5 (13.5)	6 (10.5)	7 (10.9)	5 (14.3)	7 (12.5)	2 (9.1)
SD	10 (10.1)	7 (9.0)	0	4 (10.8)	6 (10.5)	7 (10.9)	3 (8.6)	6 (10.7)	2 (9.1%)
PD	52 (52.5)	45 (57.7)	2 (40.0)	17 (45.9)	33 (57.9)	39 (60.9)	13 (37.1)	30 (53.6)	12 (54.5)
NE	1 (1.0)	1 (1.3)	1 (20.0)	0	0	0	1 (2.9)	1 (1.8)	0
NA†	12 (12.1)	10 (12.8)	1 (20.0)	7 (18.9)	4 (7.0)	2 (3.1)	10 (28.6)	8 (14.3)	3 (13.6)

n (%)	All patients (N = 99)	Refractory to last regimen (n = 78)	Prior LOT			Age, y		Immunophenotype
n (%)	All patients (N = 99)	Refractory to last regimen (n = 78)	1 (n = 5)	2 (n = 37)	>2 (n = 57)	<75 (n = 64)	≥75 (n = 35)	Germinal center (n = 56)	Nongerminal center (n = 22)
ORR∗	24 (24.2)	15 (19.2)	1 (20.0)	9 (24.3)	14 (24.6)	16 (25.0)	8 (22.9)	11 (19.6)	5 (22.7)
CR	12 (12.1)	6 (7.7)	0	4 (10.8)	8 (14.0)	9 (14.1)	3 (8.6)	4 (7.1)	3 (13.6)
PR	12 (12.1)	9 (11.5)	1 (20.0)	5 (13.5)	6 (10.5)	7 (10.9)	5 (14.3)	7 (12.5)	2 (9.1)
SD	10 (10.1)	7 (9.0)	0	4 (10.8)	6 (10.5)	7 (10.9)	3 (8.6)	6 (10.7)	2 (9.1%)
PD	52 (52.5)	45 (57.7)	2 (40.0)	17 (45.9)	33 (57.9)	39 (60.9)	13 (37.1)	30 (53.6)	12 (54.5)
NE	1 (1.0)	1 (1.3)	1 (20.0)	0	0	0	1 (2.9)	1 (1.8)	0
NA†	12 (12.1)	10 (12.8)	1 (20.0)	7 (18.9)	4 (7.0)	2 (3.1)	10 (28.6)	8 (14.3)	3 (13.6)

LOT, line of therapy; NA, not assessed; NE, not evaluable; SD, stable disease.

Per Lugano criteria.

Patients with no postbaseline overall assessment.